JP2019511553A5 - - Google Patents

Download PDF

Info

Publication number
JP2019511553A5
JP2019511553A5 JP2018554360A JP2018554360A JP2019511553A5 JP 2019511553 A5 JP2019511553 A5 JP 2019511553A5 JP 2018554360 A JP2018554360 A JP 2018554360A JP 2018554360 A JP2018554360 A JP 2018554360A JP 2019511553 A5 JP2019511553 A5 JP 2019511553A5
Authority
JP
Japan
Prior art keywords
cancer
composition
inhibitor
composition according
dyrk1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018554360A
Other languages
English (en)
Japanese (ja)
Other versions
JP7278776B2 (ja
JP2019511553A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/027734 external-priority patent/WO2017181087A1/en
Publication of JP2019511553A publication Critical patent/JP2019511553A/ja
Publication of JP2019511553A5 publication Critical patent/JP2019511553A5/ja
Application granted granted Critical
Publication of JP7278776B2 publication Critical patent/JP7278776B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018554360A 2016-04-15 2017-04-14 静止細胞標的化および有糸分裂の阻害剤を用いた新生物の処置のための組み合わせ Active JP7278776B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662323583P 2016-04-15 2016-04-15
US62/323,583 2016-04-15
PCT/US2017/027734 WO2017181087A1 (en) 2016-04-15 2017-04-14 Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis

Publications (3)

Publication Number Publication Date
JP2019511553A JP2019511553A (ja) 2019-04-25
JP2019511553A5 true JP2019511553A5 (https=) 2020-06-11
JP7278776B2 JP7278776B2 (ja) 2023-05-22

Family

ID=60039311

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018554360A Active JP7278776B2 (ja) 2016-04-15 2017-04-14 静止細胞標的化および有糸分裂の阻害剤を用いた新生物の処置のための組み合わせ

Country Status (11)

Country Link
US (3) US10314843B2 (https=)
EP (1) EP3443351A4 (https=)
JP (1) JP7278776B2 (https=)
KR (2) KR102494172B1 (https=)
CN (1) CN109313197A (https=)
AU (2) AU2017248807A1 (https=)
BR (1) BR112018071023A2 (https=)
CA (1) CA3020978A1 (https=)
IL (2) IL292475A (https=)
MX (2) MX2018012508A (https=)
WO (1) WO2017181087A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109562176A (zh) 2016-04-15 2019-04-02 费利克斯疗法公司 使用静止细胞靶向和egfr抑制剂的用于治疗肿瘤的组合
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE024568T2 (hu) * 2009-09-11 2016-02-29 Amgen Inc N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamin antimitotikus szerre rezisztens rák kezelésében történõ alkalmazásra
US20120184562A1 (en) 2011-01-19 2012-07-19 Kin-Chun Luk 1,6- and 1,8-naphthyridines
CN103797002B (zh) * 2011-08-19 2017-02-22 迪亚克森海特公司 Dyrk1抑制剂及其用途
FR2993317B1 (fr) 2012-07-16 2014-08-15 Snecma Carter de turbomachine dans un materiau composite et procede de fabrication associe
EP2999698A1 (en) * 2012-10-10 2016-03-30 Felicitex Therapeutics, Inc. Treatment of cancer by targeting quiescent cancer cells
HK1219879A1 (zh) * 2013-06-11 2017-04-21 Bayer Pharma Aktiengesellschaft 用於治疗癌症的包含mps-1激酶抑制剂和有丝分裂抑制剂的组合
CA2854542A1 (en) * 2013-06-18 2014-12-18 4Sc Discovery Gmbh Method of inhibiting dyrk1b
WO2015116696A1 (en) 2014-01-28 2015-08-06 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
MX2016012208A (es) 2014-03-20 2017-01-26 Samumed Llc Indazol-3-carboxamidas 5-substituidas y preparacion y uso de las mismas.
US20170304313A1 (en) 2014-10-06 2017-10-26 Novartis Ag Therapeutic Combination For The Treatment Of Cancer
CN108135871B (zh) * 2015-07-23 2022-11-04 博蔚医药生物科技股份有限公司 阻断疾病的泛素化-蛋白酶体系统的胺萘醌化合物及医药组合物
CN109562176A (zh) 2016-04-15 2019-04-02 费利克斯疗法公司 使用静止细胞靶向和egfr抑制剂的用于治疗肿瘤的组合

Similar Documents

Publication Publication Date Title
JP2019511553A5 (https=)
IL292475A (en) Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis
JP2010526098A5 (https=)
JP2010526097A5 (https=)
MX372716B (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen.
PH12015502563B1 (en) Bipyrazole derivatives as jak inhibitors
JP2014176384A5 (https=)
EA201490357A1 (ru) Индазолы
NZ626942A (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
JP2021501208A5 (https=)
MY155639A (en) 2, 6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
AR037032A1 (es) Benzoimidazoles
NZ721617A (en) Heterocyclic compounds
TN2018000119A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
PE20130246A1 (es) COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SINTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO
AR098776A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas
MX2017005281A (es) Etil n-boc piperidinil pirazolo piridonas como inhibidores de janus quinasa.
PH12017500564A1 (en) Novel imidazopyridazine compounds and their use
EA201790603A1 (ru) Ингибиторы гистондеметилазы
JP2015520770A5 (https=)
CY1118559T1 (el) 2,6-διαμινο-πυριμιδιν-5-υλο-καρβοξαμιδια ως αναστολεις των κινασων συκ ή jak
WO2018035346A8 (en) KINASE INHIBITING COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING CANCER
JP2018511643A5 (https=)
CU23921B1 (es) Nuevos derivados dihidroindolonas
AR096045A1 (es) Composición farmacéutica y formulación para prevenir o tratar el síndrome de ojo seco